Navigation Links
Homogeneous tuberculosis treatment ineffective in children, UT Southwestern researchers find
Date:2/10/2011

DALLAS Feb. 10, 2011 The realization of medically treating different children uniquely may start with one of the deadliest diseases in existence: tuberculosis.

New findings by UT Southwestern Medical Center researchers indicate that the type of medications and the dosage routinely used to treat children with the disease should be individualized to each young patient in order to be effective.

The findings, available online and in the February issue of Antimicrobial Agents and Chemotherapy, show that currently recommended doses are much too low and that a child's weight, age and medical history are among a myriad of factors that can affect his or her response to a particular drug used to combat the Mycobacterium tuberculosis bacterium, which causes the disease.

"Children are growing and changing and, unlike in adults, Mycobacterium tuberculosis manifests itself in children as many different diseases, causing problems all over the body," said Dr. Tawanda Gumbo, associate professor of internal medicine at UT Southwestern and the study's lead author. "Since their immune systems are not yet fully developed, you also have to take into consideration whether a particular drug will reach the part of the body affected by the disease.

"If you aggregate all these factors age, weight, medical history, disease process it's pretty clear that you need to treat each child differently instead of following the standard dosing guidelines."

About one-third of the world's population is infected with Mycobacterium tuberculosis and 2 million people die from the disease each year. TB, the leading cause of death among people infected with HIV/AIDS, kills more people than any other disease caused by a single infectious agent, according to the National Institutes of Health. Treatment usually lasts six to 12 months and includes a combination of drugs administered simultaneously, in hopes of preventing drug resistance.

For the study, the researchers virtually simulated clinical trials involving 10,000 patients who are 10 years old or younger. The computer simulation factored in pharmacokinetics (how a body handles a drug based on heterogeneous factors) to determine how likely a dose of a given drug is to kill TB. The children were grouped into three groups: fast acetylators, meaning their bodies metabolize the drugs quickly; children ages 1 to 10 who are slow acetylators; and infants who are slow acetylators.

Dr. Gumbo's team found that the drug concentrations typically used to treat children with TB are too low and that children respond differently to the standardized medication depending partly on their age and how quickly their bodies metabolize the drug.

"Despite the desire for standardized therapy, our findings support the long-held notion that there is no 'average' or 'standard' child. It is safe to assume that with 2.2 billion children worldwide, there will be 2.2 billion different regimens needed to effectively treat tuberculosis," Dr. Gumbo said.

He said the importance of the findings is that they can be applied to many other infections, including methicillin-resistant-Staphylococcus aureus, or MRSA.

"This is the future, even for adults," Dr. Gumbo said. "Being able to individualize what drug someone gets and what dose this is the future of medicine."

Dr. Gumbo's research is funded by a 2007 NIH Director's New Innovator Award, which supports bold ideas from some of the nation's most innovative early-career scientists.

Dr. Jotam Pasipanodya, research scientist in internal medicine at UT Southwestern, and researchers from the University of KwaZulu-Natal, the Howard Hughes Medical Institute, and the Kwa-Zulu Natal Research Institute for Tuberculosis and HIV in South Africa also contributed to the study.


'/>"/>

Contact: Kristen Holland Shear
kristen.hollandshear@utsouthwestern.edu
214-648-3404
UT Southwestern Medical Center
Source:Eurekalert

Related medicine news :

1. Older people and those with HIV are more vulnerable to tuberculosis
2. UN Foundation President Timothy E. Wirth Commends African Leaders for Renewed Commitment to the Global Fund to Fight AIDS, Tuberculosis and Malaria
3. Major funding awarded to improve treatment of drug-resistant tuberculosis and HIV co-infection
4. A breakthrough in tuberculosis research
5. A*STAR and Institut Merieux/bioMerieux invest S$3m ($2.2m) in tuberculosis research
6. New genomic marker for tuberculosis may help identify patients who will develop the disease
7. New dual recognition mechanism discovered in tuberculosis
8. Einstein scientist awarded $4 million to develop genetic strategy to combat tuberculosis
9. Study finds evidence of increased lung cancer risk among tuberculosis patients
10. Despite Treatment, Employees with Depression Generate Higher Absentee Costs, According to Thomson Reuters Study
11. Women More Likely to Fail Treatment for Atrial Fibrillation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... Michigan (PRWEB) , ... June 26, 2016 , ... On ... as sponsor of the 2016 Cereal Festival and World’s Longest Breakfast Table in Battle ... honor of the city’s history as home to some of the world’s leading providers ...
(Date:6/26/2016)... ... June 26, 2016 , ... PawPaws brand pet supplements ... was developed to enhance the health of felines. The formula is all-natural and is ... herbs in the PawPaws Cat Kidney Support Supplement Soft Chews are Astragalus ...
(Date:6/26/2016)... Orion, Clarkston, Michigan (PRWEB) , ... June 26, ... ... with respect to fertility once they have been diagnosed with endometriosis. These women ... intercourse but they also require a comprehensive approach that can help for preservation ...
(Date:6/25/2016)... TX (PRWEB) , ... June 25, 2016 , ... Austin ... of the American College of Mohs Surgery and to Dr. Russell Peckham for medical ... and highly effective treatment for skin cancer. The selective fellowship in Mohs Micrographic Surgery ...
(Date:6/25/2016)... ... 25, 2016 , ... "With 30 hand-drawn hand gesture animations, FCPX users can ... CEO of Pixel Film Studios. , ProHand Cartoon’s package transforms over 1,300 hand-drawn ... X . Simply select a ProHand generator and drag it above media or text ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... 2016  MedSource announced today that it has ... solution of choice.  This latest decision demonstrates MedSource,s ... their clients by offering a state-of-the-art electronic data ... nowEDC as the EDC platform of choice in ... "nowEDC has long been a preferred EDC platform ...
(Date:6/23/2016)... -- Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that ... PCT (procalcitonin) assay as a dedicated testing solution for ... clearance, Roche is the first IVD company in the ... risk assessment and management. PCT is a ... in blood can aid clinicians in assessing the risk ...
(Date:6/23/2016)... , June 23, 2016 , ... on Thursday, July 7, 2016 , , , , LOCATION: ... , , , , EXPERT PANELISTS:  , , , ... Senior Industry Analyst, Christi Bird; Senior Industry Analyst, Divyaa Ravishankar and ... The global pharmaceutical industry is witnessing an exceptional era. ...
Breaking Medicine Technology: